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1. Introduction 
We evaluated the incidences of metabolic syndrome (MS) and its components in the urban 
residents of southern China, analyzed their relationship to insulin resistance (IR), meanwhile 
compared the different of MS diagnostic criteria between Chinese Diabetes Society (CDS) and 
International Diabetes Federation (IDF) in clinic practice in the southern urban residents of 
China. The total incidence of MS was 8.7% according to the diagnostic criteria of CDS, but up 
to 19.8% according to the diagnostic criteria of IDF. The total incidences of hypertension, 
abdominal obesity and diabetes were 22.1%, 39.2% and 6.7%, respectively. The incidence of IR 
was 5.0% according the value of HOMA-IR. By means of binary logistic regression analysis, 
impaired fasting glucose, diabetes, obesity, abdominal obesity, elevated triglyceride and high 
sensitivity C reactive protein were independent risks of insulin resistance, but gender, 
hypertension, elevated low density lipoprotein and total cholesterol were not independent 
risks of insulin resistance. It is suggested by the data of our present screening in the residents 
of southern China that the incidence of MS according to the diagnostic criteria of CDS was 
lower than that according to the diagnostic criteria of IDF. Some residents with MS main 
presentation of abdominal obesity would be missed diagnosis by the criteria base on BMI. In 
the components of MS, hypertension, abdominal obesity and lower high density lipoprotein 
were more common than others. IR was associated to most of the components of MS and may 
be one of the main pathogenic factors. 
By means of cross-section epidemiological analysis, we investigated the relationship of 
glycometabolic disorder and IR with chronic kidney diseases (CKD). The prevalence of CKD 
was 12.6% in the community population, with 11.2% in the youth group, 19.4% in the 
middle age group and 17.7% in the elder group. And there were a significantly difference 
between the three age groups (P<0.01). The awareness rates and treatment rates of CKD 
were very low in all of the three groups. In the whole screened population there was a 
higher CKD prevalence in IR residents when compared to non-IR residents, 36.9% versus 
12.6% (P<0.01). Among population with only impair FBG but not diabetes, CKD prevalence 
in those residents with IR was higher than those without IR, 33.3% versus 16.0% (P<0.05). 
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Even among population with normal FBG, CKD prevalence in those residents with IR was 
higher than whose without IR, 39.1% versus 12.0% (P<0.01). It was observed in different age 
group that the prevalence of albuminuria and the mean albuminuria level were higher in 
the residents with IR when compared to the residents without IR. No difference existed 
between either the prevalence of decreasing eGFR or the mean level of eGFR in residents 
with IR and without IR in the middle age group and the old group, but not in the youth 
group in which. The mean level of eGFR was significantly higher in the residents with IR 
when compared to the residents without IR (P<0.01). It is indicated in our data that CKD is 
common and the awareness rate and treatment rate are very low in this investigated 
community population. IR might be associated with the increasing prevalence of CKD, 
especially with the increased prevalence of microalbuminuria, even in the population with 
normal FBG. Furthermore IR might also be associated with elevated eGFR in population at 
the early stage of diabetes but without CKD, while associated with decreased eGFR in those 
with CKD. It is suggested that IR might be a risk factor of CKD and also a prevention and 
treatment target of CKD in community residents. 
We also explored the incidences of hyperuricemia (HUA) in the urban residents and the 
related risk factors. The total incidence of HUA was 23.5% in the cohort residents, and was 
28.4% in the males and 19.7% in the females (P<0.01). The serum uric acid level was positively 
related to body weight (or BMI), waist circumference and the age (for females) when 
controling with serum creatinine (P<0.01). Alcohol consumption and smoke influences 
significantly on the serum uric acid level, and highest uric acid levels were in the residents 
frequently drunk and smoked in the past. More common prevalence of HUA was in the 
patients with chronic kidney disease and hypertension, and the serum uric acid levels were 
similar in these patients. There was no significant difference of the incidences of HUA between 
the patients with diabetes and non diabetes. It is suggested by our present investigation that 
the incidence of HUA is increasing in the residents of inland city of China, and that the change 
of their lifestyle with lose weight, prevention of obesity, avoid smoke and restriction of alcohol 
would be the most effective measures to change the high prevalence of HUA. 
2. Pathogenesis of metabolic syndrome associated kidney damage 
2.1 Insulin resistance and pathogenesis of metabolic syndrome-associated kidney 
damage 
Insulin resistance and metabolic renal damage is closely related. So the metabolic syndrome 
were screened for kidney damage, assessment is very necessary. Regarding to the 
pathogenesis of insulin resistance and to improve the treatment based on will also be a 
metabolic control of renal damage in a new direction for the future. 
2.1.1 Insulin resistance leads to kidney damage 
The metabolic syndrome (MS) was defined as the presence of 3 or more of the following risk 
factors: elevated blood pressure, insulin resistance, low high-density lipoprotein cholesterol 
level, high triglyceride level, elevated glucose level, and abdominal obesity. MS disease risk 
factors in order to gather more focus is characterized by heart, kidney blood vessels and 
other target organs. The impact is clear. Now the increasing number of researches show that 
compared with simple hypertension, metabolic syndrome is more easily lead to kidney 
damage. Some studies further confirmed that the large vessels and kidney of metabolic 
syndrome patients damaged obvious. MS can cause kidney damage, and the kidney disease 
affects MS as well. This shows the relationship between MS and kidney disease is very close. 
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So people consensus that MS is started for obesity as the common factor. And insulin 
resistance is the central link of MS. This can be inferred that the relationship between insulin 
resistance and metabolic renal damage is close.  
Insulin resistance refers to the uptake of insulin to promote peripheral tissue, the use of 
glucose output and inhibit the biological effects of glycogen decreased, with the changes in 
the compensatory ability of the body showed hyperinsulinemia and (or) high blood sugar 
status. The kidney damage mechanisms caused by high blood sugar is including that: 遖 
polyol pathway activation; 遘 protein non-enzymatic glycation (advanced glycation end 
products formation); 遞 activation of protein kinase C. The renal injury is caused by these 
lesions and GBM thickening. In addition, the recent study found, MS appears 
hyperinsulinemia is also often high viremia of amylin, amylin is a high-fiber protein, mainly 
deposited in the glomerular mesangial area widened, K-W nodules, blood vessel walls and 
renal interstitial, which become one of the causes of injury about glomerular and interstitial. 
In vitro experiments showed that amylin may be higher in mesangial cells through 
induction of apoptosis and increased permeability in endothelial cells kidney damage, but 
the exact mechanism is still not very clear.[1, 2]  
Now that insulin resistance occurs most often in patients with metabolic syndrome, is the 
central link in the pathogenesis and pathogenic basis. It not only prompts a new-onset diabetes 
mellitus, cardiovascular events and all-cause mortality in high-risk, but also the renal damage 
and failure are independent risk factors.[3-6] The primary kidney disease before there is often 
severely impaired renal function also showed insulin resistance.[4] Therefore, insulin 
resistance and renal damage can reinforce each other, so to clear the relationship  between 
insulin resistance and metabolic  renal damage is useful that in the prevention and treatment 
of kidney disease is especially prominent role in the process. This article is the review on the 
causes of pathogenesis why insulin resistance leads to metabolic kidney damage. 
2.1.2 Insulin resistance and pathogenesis of metabolic syndrome-associated kidney 
damage 
Insulin resistance is the central link of metabolic syndrome. The U.S. NHANES Ш data 
shows that the prevalence of metabolic syndrome has reached 23.7% for the adults who over 
20 years ’old.[3] The study showed that In type 2 diabetes, more severe insulin resistance is 
independently associated with microalbuminuria.[5, 6] Animal experiments confirmed that 
clinical diabetes mellitus in the event of hyperinsulinemia stage before changes of structure 
and function in kidney have been.[7] Such early renal damage has its own characteristics 
and pathogenesis, which are different from diabetic nephropathy. Insulin resistance 
mechanisms lead to kidney damage mainly in the following areas. 
Insulin-like growth factor (IGF) axis is involved in diabetic renal disease 
Insulin-like growth factor I (IGF-I) is a potent mitogenic polypeptide under the regulation of 
growth hormone (GH). Evidence of significant involvement of the GH/IGF system in diabetic 
nephropathy and other nephropathies has been provided by several studies. Kidney tissue 
expresses receptors not only for IGF-I but also for GH, which suggests that although most of 
the biologic effects of GH are mediated by IGF-I, GH may also act independently of IGF-I. IGF-
I may have pathogenic roles in diabetic nephropathy and other nephropathies. Serum IGF-I 
levels are reduced in hyperglycemic diabetic subjects, despite elevated GH levels. This 
phenomenon has been explained by inhibition of hepatic IGF-I synthesis, resulting from 
decreases in hepatic GHR expression and binding. The metabolic consequences of these 
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alterations produce a "vicious cycle," wherein the hyperglycemia/insulinopenia induce 
decreases in serum IGF-I levels, which in turn induce GH hypersecretion, making optimal 
metabolic control more difficult to achieve.[8] People speculate that the mechanism underlying 
the renal effects of this GHR antagonist involves renal GHR inhibition of renal IGF-I (and 
IGFBP-1) protein accumulation. They also speculate that the mechanism underlying the renal 
effects of this GHR antagonist involves renal GHR inhibition of renal IGF-I (and IGFBP-1) 
protein accumulation. This study demonstrates that the GH/IGF axis plays a central role in the 
pathogenesis of early diabetic renal changes, and it suggests specific GHR blockade as a new 
concept in the treatment of diabetic kidney disease.[9] 
Insulin resistance increase renal damage through the rennin-angiotensin system 
Angiotensin II (Ang II) and insulin are implicated in the mesangial cell hypertrophy and 
excessive accumulation of mesangial matrix seen in glomerulosclerosis. Therefore, the 
effects of Ang II with and without insulin on mRNA levels of several important extracellular 
matrix genes and transforming growth factor beta-1 (TGF-beta 1) were examined. The 
results of the studies suggest that insulin, itself, significantly increases TGF-beta 1 and 
extracellular matrix gene expression in rat mesangial cells. Ang II alone has modest effects, 
while Ang II and insulin have additive effects. To explain the mechanism of these additive 
effects, we investigated the action of Ang II on insulin signaling and the effect of insulin on 
Ang II AT1 receptor mRNA expression. Ang II did not enhance insulin-induced insulin 
receptor substrate-1 (IRS-1) phosphorylation or phosphatidylinositol 3 (PI-3) kinase activity, 
but did enhance insulin-induced mitogen activated protein (MAP) kinase activity.[10] 
Insulin increased message levels of AT1 receptor by twofold. These results suggest that 
enhancement of MAP kinase activity and AT1 receptor regulation by insulin may contribute 
to the additive effects of insulin and Ang II in mesangial cells. 
The direct impact of insulin resistance on kidney 
Insulin major role in the tubules, but the specific sites of action are not yet entirely clear.It has a 
strong role in preserving sodium and dose dependent, while the presence of insulin to counter, 
this is still Paul sodium. Therefore, insulin resistance and hyperinsulinemia that occurs when 
the sodium sensitivity of blood pressure increase in glomerular pressure increased, resulting in 
microalbuminuria. A study was performed by Vedovato M to measure the effect of Na+ intake 
on blood pressure and albuminuria, in relation with insulin sensitivity and kidney 
haemodynamics, in Type 2 diabetic patients with and without microalbuminuria. They found 
that high salt intake increases blood pressure and albuminuria in Type 2 diabetic patients with 
microalbuminuria. These responses are associated with insulin resistance and increased 
glomerular pressure. Insulin resistance could contribute to greater salt sensitivity, increased 
glomerular pressure and albuminuria.[11] 
Insulin resistance increase the renal damage by the plasminogen activator inhibitor 1  
The insulin resistance syndrome typically features glucose intolerance and elevated fasting 
insulin and triglyceride levels. Elevated levels of PAI-1 and tPA antigens associated with 
glucose intolerance, hyperinsulinemia, and hypertriglyceridemia support inclusion of 
impaired fibrinolysis as an additional feature of the insulin resistance syndrome. Elevated 
fibrinolytic factors are also correlated with elevated markers of inflammation and 
endothelial dysfunction, which has been hypothesized to cause insulin resistance and 
thereby be the common pathogenic mechanism underlying atherosclerosis, insulin 
resistance, and glucose intolerance.[12] Hagiwara H’s study proved that renal PAI-1 gene 
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expression is up-regulated in both type 1 and type 2 diabetic rats, and changes in gene 
expressions of fibrinolytic factors may play important roles in the development and 
pathogenesis of diabetic nephropathy.[13] In addition, TGF-ǃ, angiotensin П and thrombin 
could stimulate the synthesis of PAI-1, the process by inhibiting fibrinolysis and plasmin-
mediated matrix metalloproteinase activity, so that less matrix degradation, resulting in 
renal fibrosis. 
Insulin resistance increases the rates of renal damage by endothelin (ET) -1 
Endothelin-1, released from the vascular endothelium after cleavage from big endothelin-1, 
is a potent paracrine vasoconstrictor peptide. Small studies suggest that the circulating level 
of endothelin-1 is elevated in subjects with cardiovascular risk factors. High endothelin-1 
level may better reflect endothelin-1 generation. It is indicated by studies that endothelin-1 
level is not related to blood pressure, but higher in healthy young men with insulin 
resistance and obesity.[14] It was discovered in a diabetic mouse model treated with A-type 
ET receptor antagonist that glomerular TGF-ǃ and collagen I, II, IV production were 
decreased. 
Insulin resistance increase the renal damage through oxidative stress 
Insulin-stimulated (or inhibited) pathways retain normal sensitivity to the hormone, 
hyperinsulinemia could, by its effects on antioxidative enzymes and on free radical 
generators, enhance oxidative stress. Other effects of insulin involve the inhibition of 
proteasome and the stimulation of polyunsaturated fatty acid (PUFA) synthesis and of nitric 
oxide (NO).[15] Prabhakar SS attempted to review the existing literature, discuss the 
controversies, and reach some general conclusions as to the role of NO production in the 
diabetic kidney. He found that genetic polymorphisms of the NOS enzyme also may play a 
role in the NO abnormalities that contribute to the development and progression of diabetic 
nephropathy.[16] 
Insulin resistance increases renal damage through nitric oxide 
The results of study performed by Steinberg HO argued that insulin effect on the 
endothelium is mediated by its own receptor and insulin signaling pathways, resulting in 
the increased release of nitric oxide. The vascular actions of insulin are impaired in insulin-
resistant conditions such as obesity, Type II (non-insulin-dependent) diabetes mellitus and 
hypertension, which could contribute to the excessive rate of cardiovascular disease in these 
groups. Insulin-resistant state in obesity and Type II diabetes shows a multitude of 
metabolic abnormalities that could cause vascular dysfunction. Non-esterified fatty acid 
level increased long before hyperglycaemia becomes present.[17] Under the circumstance of 
insulin resistance, endothelial dysfunction leads to vascular complications in the central 
link, which results in microalbuminuria. 
2.2 Hypertension and pathogenesis of metabolic syndrome-associated nephropathy 
The abnormality of kidney structure and function caused by hypertension is called 
hypertensive renal damage. Arteriolar nephrosclerosis is the most characteristic pattern in 
hypertensive renal damage, including benign arteriolar nephrosclerosis and malignant 
arteriolar nephrosclerosis. The former caused by benign hypertension, the latter caused by 
malignant hypertension. Sustained hypertension can cause renal arteriolosclerosis for 5-10 
years (tunica intimal thickening of arcuate artery and interlobular arteries, hyaline of 
afferent artery), wall thickening, lumens narrowing, and secondary ischemic renal 
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parenchyma ischemic lesions, including glomerular ischemic shrinkage, sclerosis, tubular 
atrophy, interstitial infiltration of inflammatory cells and fibrosis, which lead to benign 
arteriolar nephrosclerosis. Malignant arteriolar nephrosclerosis is an accelerated 
hypertension or malignant hypertension-induced renal damage. 
2.2.1 Pathogenesis of benign arteriolar nephrosclerosis  
Factor of hemodynamics 
Due to normal autoregulatory mechanism of renal vessels, renal blood flow (RBF) can be 
kept relatively stable, which can protect the kidney from blood pressure fluctuation. Renal 
arteriolar constrictive response occurs in the presence of hypertension, which increase renal 
vascular resistance and decrease renal blood flow (RBF). The degree of contraction of 
efferent arteries is more significant than afferent arteries in early stage. Glomerular filtration 
rate (GFR) can still be maintained within the normal range. With the progress of 
hypertension, there is renal arteriosclerosis, compliance decreasing, arterial wall thickening, 
lumens stenosis, and RBF further decline, GFR falling, which lead to ischemic renal lesions. 
Impairment of kidney tubules secondary to ischemia is more sensitive than glomeruli. 
Furthermore, renal tubular load does not reduce for maintaining normal GFR, thus more 
likely to increase renal tubular injury secondary to glomerular hyperperfusion.[18] 
However, benign arteriolar nephrosclerosis has obvious individual differences. There is not 
observed renal arteriolar sclerosis in some glomerulosclerosis secondary to hypertension. 
Hypertensive renal injury is not completely ischemic lesions. In addition to ischemic 
hypoperfusion nephron, the recent view is that most hypertensive renal damage is 
characterized by hypertransfusion compensatory nephron. The existence of glomerular 
hyperperfusion, high pressure and high filtration promote renal parenchyma lesions, 
especially is the major pathogenesis of glomerulosclerosis.[19].  
Under hypertension state, renal vascular sensitivity to Ang II was significantly enhanced.  
Renal vascular resistance increased in the patients with hypertension who are injected low 
dose Ang II, and did not significantly change in normal people. The mechanism of 
proteinuria occurence is currently considered that increased RAS activity lead to podocyte 
fracture membrane damage and basilar membrane permeability increasing. High intra-
glomerular pressure and high shear stress-induced endothelial cell injury and dysfunction, 
activated local lesions, increased Ang II and aldosterone, induced renal vascular remodeling 
and renal arteriosclerosis.[20] 
Non-hemodynamic factors 
In hypertension state, vascular endothelium bear high pressure and shear stress, cause 
endothelial cell injury, injured endothelial cell can lease cytokines, such as transforming 
growth factor ǃ (TGF-ǃ), plasminogen activator inhibitor (PAI).[21] Hypertension can 
directly cause renin-angiotensin-aldosterone system activation and oxidative stress. These 
factors can cause together kidney damage, matrixfibrosis and tissue hardening.[22, 23] 
Clinically nephroangiosclcrosis may occur before significant elevation of blood pressure, 
such as unilateral nephrectomy or early type 1 diabetes mellitus (TIDM). Glomerular 
capillary blood flow is still significantly increased. Therefore, the renal capillary pressure 
overload, it can lead to nephrosclerosis. high pressure and high shear in glomerular cause 
endothelial cell dysfunction, which could lead to increase in some active factors such as 
angiotensin II (Ang II), endothelin-1(ET-1), thromboxane A2 (TXA2), TGF-ǃ2 and platelet-
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derived growth factor (PDGF) factors, leading to vasoconstriction, mesangial cell 
proliferation and collagen deposition, promoting ECM synthesis and secretion. The high 
pressure in glomeruli can also lead to glomerular visceral epithelial cell injury, increasing 
permeability of the basement membrane, causing proteinuria, eventually leading to 
glomerulosclerosis, nephron loss. Therefore, the patients with essential hypertension have 
low perfusion of ischemic nephron and high perfusion nephron, the latter is more 
characteristic pattern.  
In addition, reactive oxygen species, salt intake, lithium-sodium counter-transport 
abnormalities, racial and genetic backgrounds, metabolic disorders, age, gender, body mass 
index, smoking is also influencing factors. 
In summary, hypertensive renal damage is secondary to vascular lesions caused by high 
arterial pressure. The main mechanism of hypertensive renal damage is hemodynamics 
abnormalities in glomerular, and cytokines, vasoactive substances and the ECM are 
involved in the disease process. 
2.2.2 Pathogenesis of malignant arteriolar nephrosclerosis 
The direct vascular injury of elevated blood pressure  
When blood pressure is significant elevated, renal artery and glomerular capillary stress and 
shear stress can be changed, which induce endothelial cells to secrete varied adhesion 
molecules, promoting inflammatory cell adhesion to endothelial cells, leading to endothelial 
cell damage.[24] Vascular endothelial cell damage lead to increased permeability, plasma 
protein and fibrinogen deposition in the vessel wall, induce vascular fibrinoid necrosis and 
tunica intimal damage. Finally, it appears vascular lumen narrowed and renal ischemia. But 
some patients with severe and persistent hypertension, whose vascular injury can not 
become malignant state. It indicates that in addition to intravascular pressure, there are 
other factors involved in vascular damage.     
Activation of renin-angiotensin-aldosterone system (RAAS) and endothelin  
Malignant hypertension often accompanied with activation of RAAS, It should be noted that 
the activation of RAAS may be primary or secondary. Activation of RAAS can promote 
intermittent vasoconstriction, activate platelets, release thromboxane and platelet derived 
growth factor (PDGF), stimulate myointimal cell migration and proliferation, cause vascular 
lumen narrowed, increased level of blood pressure and renal ischemia. When the systolic 
pressure is over 180-190mmHg critical level, it can occur naturally natriuretic and diuretic 
phenomenon, the decline in blood volume can further activate the RAAS.[25] In addition, 
elevated angiotensin can  promote inflammatory cells adhesion to endothelial cell, induce 
apoptosis of endothelial cells, damage the integrity of blood vessels, induce fibrinoid 
necrosis of arteriole by "vascular toxicity".[26] Endothelin is of powerful vasoconstrictor 
function, it can cause sustained elevation of blood pressure. Animal model of malignant 
hypertension has been confirmed to plasma endothelin and endothelin-mRNA expression in 
renal tissue increased.[27]  
Microvascular coagulation and thrombosis 
Hypertension damage vascular endothelial, which active directly coagulation system, lead 
to platelet aggregation and fibrin deposition in vascular lumen. When red blood cells pass 
through the damaged vascular lumen, it prone to result in damage and lead to 
microvascular coagulation. Meanwhile, both platelet aggregation and adhesion of 
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leukocytes on vessel wall lead to turbulence, promoting to form platelet micro-
thrombus.[28] 
Genetic factors 
It is reported that HLAB15, DR3, BW35 and CW4 are significantly associated with the 
incidence of malignant hypertension.[29, 30]  
2.3 Lipid metabolic disorders and pathogenesis of metabolic syndrome-associated 
nephropathy 
Lipid metabolism and kidney disease are closely related. As early as 1982, Moorhead[31] 
proposed that lipid accumulation can lead to chronic renal injury, it is not only a lot of 
primary or secondary renal diseases with common clinical manifestations, but also the 
progress of the diseases.[32] Hyperlipidemia, in addition to proteinuria and hypertension, 
promotes CKD progression outside the third most important factor. In polycystic kidney 
disease, obesity, diabetes and hypertension in animal models, hypercholesterolemia were 
found to accelerate the progress of kidney diseases, and high-fat diet can induce kidney 
macrophages and foam cell formation leaching, resulting in glomerular sclerosis.[33] In 
obese Zucker rats, lowering serum triglycerides improves glomerular sclerosis.[34] These 
results suggest that lipid metabolism is closely related with renal dysfunction, and a series 
of clinical studies have also been to the same conclusion. Samuelsson et al[35] found 
triglyceride-rich lipoproteins containing Apo-B in patients with CKD are closely related to 
the progress of the disease; Muntner et al[36] found in 12 728 subjects with normal renal 
function that low HDL cholesterol and hypertriglyceridemia in individuals with impaired 
renal function appeared more dangerous. 
2.3.1 Mesangial cell function 
Regulation of glomerular filtration of mesangial cells to produce matrix components, 
involved in the development of many glomerular diseases. Mesangial cell surface LDL, 
oxidized HDL and very low density lipoprotein act through receptor pathway and the 
corresponding lipoproteins. LDL can bind to mesangial cells and mesangial cell function can 
offset.[37] LDL stimulates mesangial cells and had a "phase effect", ie, low concentration of 
LDL stimulates cell proliferation, and high concentrations inhibits cell proliferation as toxic 
cells effect. The effect of LDL promoting mesangial cell proliferation may be related to 
arachidonic acid metabolism. Mesangial cells cytochrome P450 monooxygenase system 
produces epoxide metabolic pathways, it can promote cell proliferation, LDL oxidation and 
the formation of more toxic OX-LDL in a dose dependent manner, which can further 
increase mesangial cell injury. The mesangial cells and macrophages form foam cells and 
release cytokines and growth factors, such as transforming growth factor ǃ, tumor necrosis 
factor, platelet derived growth factor and interleukin-1 and so on. These cytokines can 
stimulate the LDL receptor gene transcription and expression of epithelial cells, mesangial 
cells and macrophages, and promote the deposition of lipid in kidney cells and induced 
renal injury.[38] Mesangial cells themselves can be oxidized by LDL. OX-LDL can induce 
apoptosis of mesangial cells. 
2.3.2 Mesangial matrix 
Glomerular mesangial matrix includes type IV collagen, fibronectin and laminin. LDL and 
LDL oxidation in vitro can stimulate the increase of extracellular matrix components. LDL 
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can be activated in mesangial cells by LDL protein kinase C, which promotes transforming 
growth factor-ǃ synthesis in the cells, and TGF-ǃ can stimulate the cells to produce tissue 
inhibitor of matrix metalloproteinases, inhibiting matrix degradation and leading to the 
increase of mesangial matrix.[39] It has been confirmed by in vitro experiments that lipids 
increased the expression of TGF-ǃ mRNA in mesangial cells and epithelial cells. 
2.3.3 Endothelial cells 
Endothelial cells with LDL receptor, VLDL receptor and LDL receptor related protein. 
Lipoprotein receptors and related, or non-receptor pathway, causing cell proliferation, 
lipoprotein lipase and lipoprotein receptors can enhance and strengthen its effect in 
promoting cell proliferation. OX-LDL and Lp of endothelial dysfunction caused mainly by 
interfering with the vasodilators nitric oxide synthesis and direct inactivation; and increased 
thromboxane A2 and endothelin production, damage vascular endothelial NO dependent 
relaxation response, cause renal ball efferent arteries, increasing the pressure in the 
glomerular endothelial cells to further damage, the release of cytokines, to promote cell 
proliferation, glomerular sclerosis. In addition, the lipoprotein receptor pathway through 
the endothelial cells directly mediated endothelial cell injury, while activation of coagulation 
and fibrinolytic system activation and inhibition of platelet function, leading to fibrin 
deposition and thrombosis, increased glomerular injury. 
2.3.4 Glomerular epithelial cells 
Glomerular epithelial cell surface LDL, VLDL receptor and lipoprotein receptor related 
protein, which contains both apoB and apoE, respectively, with the lipoproteins, the 
annexation of the metabolism of cells. apoE with high affinity receptors, the degree of 
cellular cholesterol esterification increased, and inhibition of cholesterol synthesis, therefore, 
glomerular epithelial cellsith more and VLDL, thus not explain the clinical 
hypercholesterolemia, only lipoprotein formed an exception. Can also cause the deposition 
of lipids in the glomeruli, glomerulosclerosis occurring phenomenon. 
2.3.5 Tubulo-interstitium 
Tubular injury showed increased tubulointerstitial matrix proteins and fibrosis. Proximal 
tubular epithelial cells present LDL, very low density lipoprotein receptor, hyperlipidemia 
lipid deposition in the renal tubules, tubular epithelial cells by phagocytosis, the formation 
of foam cells, while LDL, OX-LDL for the expression and FN mRNA secretion, further 
stimulate tubulointerstitial synthesis, promoting fibrosis. 
2.3.6 OX-LDL renal toxicity 
OX-LDL can promote renal cell proliferation, apoptosis and phenotypic transformation, 
involved in the glomerulosclerosis process from cell to cell is too small too many states the 
state of the process of cell loss.[40] OX-LDL also has the monocyte chemotactic activity of 
macrophages can express clear the OX-LDL receptor, OX-LDL uptake by macrophages 
stimulated macrophages after the synthesis of growth factors, cytokines and other related 
matrix protein synthesis in the media. Extraordinary receptor exists in glomerular mesangial 
cells and epithelial cells. In the case of lipid metabolism, the oxidation of LDL can be 
modified first intake, OX-LDL accumulation in the kidney and stimulate the kidney cells to 
secrete TGF-ǃ1 and other cytokines to promote renal fibrosis, leading to monocyte-
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macrophage in the local infiltration. Moreover, the activation of macrophages and can 
promote LDL oxidation, secretion of TGF-ǃ and PDGF-AD, caused by extracellular matrix 
and mesangial expansion, creating a vicious cycle.[41] Focal segmental glomerulosclerosis in 
animal models and human glomerular diseases, a number of chronic renal biopsy tissues 
were detected by OX-LDL deposition, and the extent of OX-LDL deposition and renal 
dysfunction and protein was positively correlated with urine. 
2.4 Hyperuricemia and pathogenesis of metabolic syndrome-associated nephropathy 
Hyperuricemia is highly prevalent in MS patients. A few studies showed that 
hyperuricemia was associated closely with progression of kidney disease.[42] About 20% to 
60% of patients with gout have mild or moderate renal failure. The histological lesion 
named "gouty nephropathy" includes glomerulosclerosis, interstitial fibrosis, and renal 
arteriolosclerosis, often with focal interstitial urate crystal deposition. 
The precipitation of uric acid in the renal medulla with formation of characteristic tophi was 
believed to activate an inflammatory response resulting in renal interstitial fibrosis, a loss of 
nephrons, and ultimately to irreversible chronic renal failure. When pH<5.5 in vivo or 
dehydration, urate can deposit in the renal tubules and interstitium which cause urate 
nephropathy. It also can form kidney stone in distal tubule and collecting duct and induce 
obstruction. Emmerson[43] found that some interstitial deposits of urate and uric acid in the 
kidney derived from intra-tubular deposits which react with the tubular epithelium and 
pass into the interstitium; loss of tubular integrity may not be a prerequisite for crystal 
migration. Toblli[44] confirmed that urate crystals deposit in renal tubular cells, evoke 
complement, platelet, inflammatory cell and macrophages by classical pathway or 
alternative pathway, induce the expression of cytokine and transforming growth factor beta 
increased; stimulate fibroblast to be fibrocyte, activate cross linkage of collagen and 
ultimately lead to renal fibrosis or renal failure.  
However, it is difficult to ascribe the generalized renal damage in gout to the deposition of 
urate crystals, for they are often only focally present. 
Recent studies have reported that mild hyperuricemia in normal rats induced by the uricase 
inhibitor, oxonic acid (OA), results in systemic hypertension, renal vasoconstriction, 
glomerular hypertension and hypertrophy, and tubulointerstitial injury independent of 
intra-renal crystal formation.[45-47] It has also been found that hyperuricemia can accelerate 
renal disease in the remnant kidney model and accelerate experimental cyclosporine 
nephropathy.[48,49] The main pathophysiological mechanism by which uric acid causes 
these conditions involves the  inhibition of endothelial nitric oxide bioavailability and direct 
actions on endothelial cells and vascular smooth muscle cells.[50,51] The importance of 
these pathways is suggested by a recent prospective study in which lowering uric acid in 
individuals with hyperuricemia and renal dysfunction was associated with improved BP 
control and slower progression of renal disease.[52]  
There are a lot of clinical evidences that hyperuricemia may induce endothelial dysfunction, as 
lowering uric acid with allopurinol can improve endothelial function as measured by brachial 
artery vasodilatation.[53] Interestingly, while both uric acid and nitric oxide (NO) exhibit 
circadian variation, serum uric acid peaks around 6 a.m. when the level of NO is lowest.[54] 
This relationship can be accounted for by the finding that uric acid also inhibits endothelial cell 
dependent vasodilatation of rat aortic rings[55] and NO production in endothelial cells.[56] 
Furthermore, uric acid blunts endothelial cell proliferation in response to serum. [56] The 
mechanism by which uric acid inhibits NO levels is complex. It may involve scavenging by 
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oxidants, which can be induced by NADPH oxidase under hyperuricemia.[57] A reduced NO 
bioavailability could also be due in part to inhibition secondary to CRP production.[56] 
In addition, the activation of RAS plays an important role in the exacerbation of renal injury 
caused by uric acid, which has been shown to be an important mediator of progression of 
renal disease, not only by its hemodynamic effects to increase systemic and glomerular 
pressure, but also by its direct fibrogenic effect in kidney and vessels. The increase of renin 
expression is observed in hyperuricemic rats. The relationship between serum uric acid and 
plasma renin activity has been described in humans.[58] Blocking the renin angiotensin 
system can ameliorate hypertension and renal injury in hyperuricemic rats.[45] 
Furthermore, studies in humans suggest that uric acid acts on blood pressure and renal 
injury in part via the renin angiotensin system.[59] All of above discoveries suggest that the 
roles of uric acid may also be mediated by the activation of the renin angiotensin system. 
Hyperuricemia also alters glomerular hemodynamics.[47] Hyperuricemia induces cortical 
renal vasoconstriction in rats as evidenced by a significant increase of afferent and efferent 
arteriolar resistances. A decrease in glomerular plasma flow and the ultrafiltration 
coefficient resulted in a 35% decrease in single nephron GFR whereas glomerular pressure 
was increased. These changes were restored by allopurinol treatment. Aberrant renal 
autoregulation appears to be responsible for the glomerular hypertension observed with 
experimental hyperuricemia. Under normal conditions, an increase in mean systemic 
arterial pressure causes a reflex vasoconstriction of the afferent arteriole, thus preventing the 
transmission of the increased pressure to the glomerular circulation. However, in the event 
that the afferent arteriolar vasoconstriction is insufficient, the transmission of increased 
pressure to the glomeruli results in glomerular hypertension.[47] While renal 
vasoconstriction occurs in experimental hyperuricemia, it may be insufficient for the degree 
of systemic hypertension, therefore glomerular pressures are increased. This may be due to 
the disease of the afferent arteriole that occurs in the hyperuricemic rats, as evidenced by an 
increase in the media to lumen ratio. Again, the observation that allopurinol was able to 
prevent arteriolar hypertrophy leading to a normal renal autoregulatory response indicates 
a potential role of uric acid on this process.[47] 
2.5 Obesity and pathogenesis of metabolic syndrome-associated nephropathy 
The metabolic syndrome is a cluster of the most dangerous heart attack risk factors: diabetes 
and prediabetes, abdominal obesity, high cholesterol and high blood pressure.[60] Abdominal 
obesity is the form of obesity most strongly associated with metabolic syndrome. Obesity and 
metabolic syndrome has been found to be independent risk factors for CKD.[3, 61, 62] Treating 
obesity might stabilize renal function or reverse early hemodynamic abnormalities and 
glomerular dysfunction.[63, 64] Since the first description of an association between massive 
obesity and nephrotic proteinuria in 1974, a specific histopathologic pattern characterized by 
glomerulomegaly, in many cases accompanied by focal segmental glomerulosclerosis, has 
been described repeatedly in obese patients without any other defined primary or secondary 
glomerular diseases (including diabetic nephropathy, hypertensive nephrosclerosis, and 
secondary focal segmental glomerulosclerosis) and now is referred to as "obesity-related 
glomerulopathy".[65, 66] Overweight, obesity, and the metabolic syndrome have recently 
emerged as strong independent risk factors for chronic kidney disease (CKD) and ESRD. The 
multivariate analysis made by Chen et al[3] showed that the risk for being affected by CKD 
was more than twice as high in patients with an increased waist circumference than in those 
without, suggesting that obesity may be an independent risk factor for CKD. 
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Obesity with the features of the metabolic syndrome causes renal dysfunction,[67] 
increase glomerular filtration rate (GFR), renal blood flow (RBF), and filtration fraction 
(FF) in experimental and clinical observations.[64, 68, 69] Obesity also increases the risk 
factor for diabetes and hypertension. Iseki[70] indicate that obesity, including metabolic 
syndrome, is a potential treatable cause of CKD and ESRD. In a large cohort of >320,000 
patients who were followed at Kaiser Permanente, Hsu et al[62, 71] found that a higher 
BMI was a strong independent risk factor for ESRD even after adjustment for other major 
risk factors that are associated with ESRD, including smoking, baseline hypertension, and 
diabetes.  
Hyperlipidemia, hyperinsulinemia, hyperleptinemia, hyperuricemia and hypercoagulability, 
together in obese patients may directly or indirectly affect renal structure and function, caused 
kidney damage. 
The pathogenesis of ORG may be implicated:  
1. Renal hemodynamic alterations: Studies in animals and in humans have shown that 
obesity is associated with elevated GFR and increased renal blood flow.[68, 71] This likely 
occurs because of afferent arteriolar dilation as a result of proximal salt reabsorption, 
coupled with efferent renal arteriolar vasoconstriction as a result of elevated Ang II. In 
addition, Ang II may have a role in the regulation of adipokine production in adipose 
tissue and may increase insulin resistance in the setting of obesity.[72, 73]  
2. Sympathetic stimulation: Obesity-related there is widespread increased sympathetic 
nerve activity, its causes and obese patients with baroreceptor dysfunction and 
vasomotor centers less on the incoming inhibitory signals.[74]  
3. Leptin: Wolf[75] studies have shown that Leptin levels in obese patients was 
significantly higher, it was upregulated in glomerular endothelial cells and mesangial 
cells. Increased TGF-ǃ1 and its receptor mRNA expression promote glomerular 
endothelial cells and mesangial cell proliferation. 
4. Inflammation: The results of several studies have suggested that adipose tissue, 
especially visceral adipose tissue, is a major source of cytokine secretion in the 
metabolic syndrome, and that inflammatory cells, especially mature bone marrow–
derived macrophages, invade adipose tissue early in obesity.[76, 77] Inflammation was 
linked to obesity and the metabolic syndrome in patients with CKD. Ramkumar et 
al[78] found a strong association between inflammation as defined by a CRP level >3 
mg/dl and a high BMI in patients with CKD.  
5. Changes in fatty acid composition in kidney, causing kidney reduced the release of 
vasoactive substances, increased the pressure of glomerular capillary. Hall et al[79] 
show that the mechanisms responsible for increased sodium reabsorption and altered 
pressure natriuresis in obesity include activation of the renin-angiotension and 
sympathetic nervous systems, and physical compression of the kidneys due to 
accumulation of intra-renal fat and extracellular matrix.  
2.6 Diabetes and pathogenesis of metabolic syndrome-associated nephropathy 
Diabetic nephropathy is the most important long-term complication of diabetes mellitus and 
a major cause of end-stage renal disease. The condition is associated with excess 
cardiovascular morbidity and mortality, as well as other diabetic microvascular 
complications.[80] The etiopathogenesis of diabetic nephropathy appears to involve both 
genetic and environmental factors leading to disease in a subgroup of patients. Improved 
knowledge of the natural history and pathophysiology of the condition have enabled 
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2.6.1 Historical background 
DN has the characteristic of obvious family accumulation, but the incidence of the disease in 
different races is very different. Diabetic nephropathy is a serious problem resulted from 
microvascular complications of diabetes mellitus. Thus, genetic factors determining 
susceptibility plays an important role in DN, which was shown by studies about 
angiotensinogen (AGT) gene, angiotensin converting enzyme (ACE) gene, aloes reeducates 
(AR) gene, Glut21 gene, endothelial cells Nitric oxide synthase (eNOS) gene, cell receptor ǃ-
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chain of fixed area (TCRǃ) genes. Correlation between gene polymorphism and the 
occurrence and development of DN has also been discovered.[82] 
2.6.2 Chronic hyperglycemia 
Hyperglycemia can activate intracellular key catalytic glucose into sorbitol AR. With high 
glucose increased AR activity, polyol metabolism in kidney is active, so that excessive 
accumulation of sorbitol and fructose. Sorbitol polarity is strong, thus can not freely through 
the membrane, while fructose has little further metabolism. It results in fructose 
accumulation and the increase of intracellular osmotic pressure and therefore cell edema. 
While the level of intracellular inositol is decreased, glutathione, NADH / NAD + ratio 
increased, Na2K2ATP activity decreased, which results in tissue hypoxia and endothelial 
cell damage, contributing to the occurrence and development of DN.[83] Some studies 
suggest that AR gene polymorphism is related to AR mRNA levels in peripheral blood 
mononuclear cells and diabetic micro-vascular complications. High glucose can lead to non-
enzymatic glycosylation reaction, formation of advanced glycation end products (AGEs) in 
many organs. AGEs bind the AGE receptor (RAGE) of vascular endothelial cells, 
macrophages, vascular smooth muscle cells, mesangial cells and other cells. RAGE, as a 
signal transduction receptor, activates mitogen-activated protein kinase pathway (MAPK) 
and nuclear factor (NF) -κB signaling pathway (cell proliferation and inflammatory 
response), Ras pathway (stress and apoptosis), Rac/Cdc-42 pathway (cell growth and 
movement), Jak / Stat pathway (regulation of gene expression), raising the expression of a 
variety of growth factors, such as platelet derived growth factor and transforming growth 
factor, basic fibroblast growth factor, and adhesion molecules, such as intercellular adhesion 
molecules-1 and vascular cell adhesion molecule.[84] 
Reactive oxygen species (ROS), including superoxide radicals, hydrogen peroxide, hydroxyl 
radicals, and lipid peroxidation, are of in vivo biological activity of inducing aerobic 
metabolism. Studies demonstrated that increased oxidative stress existed in diabetes. High 
glucose increased the generation of ROS by inhibiting the activity of the three glycerol 
phosphate dehydrogenase, leading to the development of microvascular complications 
mediated by diabetes-related signaling pathways, such as PKC pathway, polyol pathway, 
hexosamine pathway and AGEs formation. High glucose can also increase the the gene 
transcription of adhesion molecules and inflammatory NF-κB. Increased levels of ROS can 
also increase peroxynitrite synthesis and nitrotyrosine formation, leading to DNA damage, 
prompting the development of diabetic microvascular complications.[85] 
PKC activation in diabetes is a common pathway of vascular injury. PKC family, has more 
than ten isozymes and plays, mainly PKC-ǃ, a role in vascular injury in diabetes. PKC can be 
activated through a variety of ways. Hyperglycemia within the tissue cells can increase PKC 
activation, increase NADH / NAD + ratio, increase oxidative stress.[86] PKC inhibited 
endothelial nitric oxide synthase (eNOS) activity, decreasing NO level and NO-mediated 
inhibition of cyclic guanosine monophosphate (cGMP) generation, leading to vasomotor 
dysfunction.[87] PKC stimulated platelet aggregation and increased the content and activity 
of PAI-1, promoting the hypercoagulability of patients with diabetes. PKC promoted 
vascular endothelial growth factor (VEGF) expression, promoting angiogenesis, increasing 
vascular permeability.[88] PKC regulated the expression of transforming growth factor 
(TGF)-ǃ and increased the expression of fibronectin and collagen type IV, leading to 
extracellular matrix expansion. Researches had shown that TGF-ǃ promoted local 
extracellular matrix deposition. 
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2.6.3 Microvascular disorders 
Homodynamic changes in early diabetic micro-vascular disorders characterized by 
increased pressure, is generally reversible. High glucose increased the plasma osmolality, 
increasing blood volume and renal blood flow. Diabetes changed the ratio between the 
resistance of glomerular arterioles, resulting in glomerular capillary hyperperfusion and 
high pressure, the mesangial matrix expansion and basement membrane thickening, and 
therefore leading to focal glomerular sclerosis.[89] Meanwhile, the capillary endothelial cell 
was damaged, the normal filtration barrier was damaged, protein filtration was increased, 
which result in the loss of glomerular function. 
Microvascular disorders in DN is the pathological basis of clinical manifestations, the most 
prominent is the basement membrane thickening and the damage of glomerular filtration 
barrier function. The pathogenesis includes continuing glomerular hyperperfusion and 
hyperfiltration, increased collagen synthesis. Sustained high glucose leads to the non-
enzymatic glycation of basement membrane protein components. Another major 
pathological feature of DN is increased mesangial matrix. Mesangial expansion is mainly 
resulted from the following factors: glomerular hemodynamic abnormalities, increased 
capillary pressure. High filtration can stimulate the increase of mesangial matrix, the 
damage of glomerular filtration barrier. The leakage and accumulation of macromolecules in 
the membrane system stimulate mesangial cell proliferation and promote matrix 
production. High blood glucose activates protein kinase C in mesangial cell and the increase 
in mesangial matrix protein synthesis. Cellular growth factors are the important factors 
playing roles in increasing mesangial matrix. The most important of which is TGF-ǃ. High 
blood glucose, glomerular capillary pressure and angiotensin (Ang) - II can promote the 
synthesis of extracellular matrix of mesangial and tubular epithelial cell. In addition 
endothelin (ET) also stimulate the proliferation of mesangial cells and the secretion of 
matrix. NO had inhibitory effect on mesangial cells. NO level is increased in early stage of 
diabetic nephropathy, which results in glomerular hyperperfusion and hyperfiltration. And 
it is reduced in the late stage due to endothelial cell damage, which leds to the increasing of 
mesangial matrix, playing a role in accelerating glomerular injury.[90] 
In diabetes, blood flow slows down and micro-thrombosis is easy to form, mainly due to 
abnormal endothelial cell and platelet function. The increase in serum of von Willebrand factor 
(vWF) is considered a sign of vascular endothelial cell injury. vWF is synthesized by 
endothelial cells, mediates platelet adhesion to endothelium, promote thrombosis. Overseas 
studies suggest that vWF is an independent risk factor for microvascular disease in 
diabetes.[91] In addition endothelial dysfunction is also reflected by the decreased activity of 
tissue plasminogen activator (t-PA) or the incresed activity of plasminogen activator inhibitor 
(PAI) which result in decreased fibrinolytic activity. Decreased prostacyclin-2 (PGI-2) synthesis 
reduced platelet inhibition. Increased release of ET can promote platelet aggregation. Plasma ǃ 
platelet globulin (ǃ-TG) and platelet factor 4 (PF4) levels reflect platelet activation. Increased 
thromboxane (TXA) -2 synthesis promote platelet aggregation and thrombosis. Many studies 
shown that increased platelet aggregation plays a very important role in the development of 
microangiopathy in type-2 diabetes mellitus, in addition to long-term hyperglycaemia. 
2.7 Metabolic syndrome in pathogenesis of allograft renal damage 
The metabolic syndrome (MS) is a cluster of interrelated common clinical entities, which 
include obesity, insulin resistance, glucose intolerance, hypertension and dyslipidaemia. 
Insulin resistance is their common pathophysiological basis. Metabolic syndrome 
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significantly increases the risk for cardiovascular disease and chronic kidney disease.[92] 
Recently it has been found that MS is also common in renal transplant recipients. How is 
kidney transplantation complicated with metabolic syndrome? 
2.7.1 Immunosuppressive therapies 
Immunosuppressive therapies induce post-transplantation diabetes 
Post-transplantation diabetes is believed to be multi-factorial, probably involving ǃ-cell 
toxicity and increased insulin resistance. In addition to other risk factors, studies suggest 
that immunosuppressive regimens may account for a large degree of the increased risk for 
the development of post-transplantation diabetes. 
Corticosteroids and Calmodulin inhibitors (cyclosporine and tacrolimus) are widely used in 
kidney transplant recipients. They have long been recognized to potently affect glucose 
tolerance by a prevalent increase of peripheral insulin resistance. 
Increasing daily prednisolone dose was independently associated with insulin resistance as 
glucocorticoids promote gluconeogenesis in the liver, inhibit glucose uptake, diminish 
glycogen synthesis in skeletal muscle cells and also may attenuate insulin secretion from 
pancreatic beta-cells. Several mechanisms displayed in vitro studies on murine ǃ-cell or 
human cell lines incubated with dexamethasone, have been proposed: insulin secretion 
inhibition by increased expression of a2-adrenergic receptors, decreased cAMP levels, 
decreased Glut2 protein at the ǃ-cell plasma membrane, down regulation of glucokinase 
mRNA, increased voltage-gated K+channel activity, ǃ-cell apoptosis through the activation 
of the calcineurin phosphatase and the corticosteroid receptor.[93-96] 
Calcineurin inhibitors, tacrolimus and cyclosporine cause reversible toxicity to islet cells and 
may directly affect the transcriptional regulation of insulin expression. Furthermore, both 
calcineurin inhibitors impair insulin gene transcription regulation through the inhibition of 
calcineurin signalisation. Other mechanisms have been proposed: closing of the ATP-
sensitive potassium channel, interference with mitochondrial function of pancreatic ǃ-cell, 
impairment of glucose-stimulated insulin secretion downstream of the rise in intracellular 
Ca2+ at insulin exocytosis, reduced ATP production and glycolysis derived from reduced 
glucokinase activity, decreased islet cell viability by a down regulation of anti-apoptotic 
factors and accumulation of pro-apoptotic mediators in cultures of freshly isolated human 
islets. Tacrolimus is more diabetogenic than cyclosporine.[97-99] At the first, it can be due to 
the steroid mimetic effect of tacrolimus. Tacrolimus binds to FK506-binding protein (FKBP), 
predominantly FKBP-12. Another immunophilin, FKBP-52 is associated with the 
cytoplasmic glucocorticoid (GC) receptor complex. When cells are exposed to 
glucocorticoids, the steroid binds to the GC receptor and liberates it from the complex. By 
binding to FKBP-52 in the GC receptor complex, tacrolimus may alter the affinity of 
interactions and either cause a release of the GC receptor at lower steroid concentrations, a 
steroid-sparing effect, or it may free the GC receptor I absence of steroids . Second, 
tacrolimus increases the bioavailability of steroids. 
Immunosuppressive therapies induce obesity 
Prednisone can induce overweight or obesity in transplant recipients, espically abdominal 
obesity, the abdominal fat which is sensitive to catecholamine can induce insulin resistance 
through elevating the level of low density lipoprotein and very low density lipoprotein, 
inhibiting the activity of phosphofructokinase, blocking glycolysis and glucose uptake. 
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2.7.2 Virus infection 
Cytomegalovirus is one of the most important pathogenic microorganism after renal 
transplantation, Cytomegalovirus infection can infect insulin secretion, induce insulin 
resistance and  impair the function of pancreatic ǃ-cell, and it is independent infector of 
post-transplant diabetes mellitus（PTDM).[100] Cytomegalovirus infection increases the 
activity of tumor necrosis factor(TNF), TNF can affect the function of islet B cell and 
decrease the organism’s sensitivity to insulin, that will promote insulin resistance in renal 
transplant recipients. 
Patients with HCV infection were found to have a 8.3-fold higher risk of appearing PTDM 
compared with HCV(-) patient.[101] Patients with HCV disease have increased peripheral 
insulin resistance and are hyperinsulinemic, similar to those with type 2 DM. It also is 
postulated that patients with HCV have decreased ǃ-cell responsiveness, possibly caused by 
direct viral effects. Other explanations include an autoimmune pathogenesis because HCV 
has been associated with several autoimmune diseases, including cryoglobulinemia, 
Hashimoto’s thyroiditis, and Sjogren’s syndrome. This would suggest antibody-mediated 
destruction of pancreatic ǃ-cells. A potential role of viruses in the cause of type 1 DM has 
been suggested, as well as a role for enteroviruses. A greater prevalence of PTDM in 
patients with HCV therefore likely is caused by a combination of increased peripheral 
insulin resistance and either a direct viral- or immune-mediated effect of HCV on pancreatic 
ǃ-cells that results in relative insulin deficiency. 
2.7.3 Polycystic kidney disease 
Insulin resistance with compensatory hyperinsulinaemia has been reported in adult 
polycystic kidney disease patients. It is reported that post-transplant diabetes mellitus 
(PTDM) occured in 10 adult polycystic kidney disease (APKD) patients and four controls 
(34.6% vs 15.3%; P<0.005).[102] It has been shown that increased membrane fluidity and 
abnormal erythrocyte Na/Li counter-transport, both abnormalities associated with insulin 
resistance, are present in APKD patient.[103, 104] 
3. Diagnosis 
Till now there is no formal denomination of metabolic syndrome associated kidney diseases 
which are often diagnosed as obesity-associated glomerulonephropathy, diabetic 
nephropathy, hypertension-associated kidney damage, lipid disorder associated kidney 
damage and hyperuricemia-associated kidney damage.  
The diagnosis of metabolic syndrome associated renal disease is generally two levels criterion 
(Table 3-1). The first level is for large sample epidemiological screening, which is base on the 
diagnosis of MS and CKD, and often including MS complicated with CKD or CKD 
complicated with MS. The second is for clinical evaluation and treatment, which base on the 
diagnosis of MS and the clinical presentation and renal pathology of obesity-associated 
glomerulonephropathy, diabetic nephropathy, hypertension related renal damage lipid 
disorder associated kidney damage and hyperuricemia-associated kidney damage. Renal 
biopsy might be necessary for the investigation and clinical diagnosis of metabolic syndrome 
associated kidney diseases under some circumstances, and the pathological evaluation should 
be made with not only light microscope, but also immunofluorescence and electron 
microscope. The definite diagnosis of metabolic syndrome associated kidney diseases should 
exclude other primary or secondary kidney diseases. In clinical practice, metabolic syndrome 
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associated kidney diseases are often accompanied with other primary or secondary kidney 
diseases. Post-transplant metabolic syndrome associated kidney diseases are often 
complicated with acute or chronic rejection in renal allograft. 
 
Level 1 Metabolic syndrome complicated with chronic kidney disease 
1. Consistent with the diagnosis criterion of metabolic syndrome (necessary). 
2. Consistent with the chronic kidney disease (necessary). 
 
Level 2 Metabolic syndrome associated kidney disease 
1. Consistent with the diagnosis criterion of metabolic syndrome (necessary). 
2. One of the following diagnosis criterions. 
i. The obesity patient with the renal pathological character of obesity- associated 
glomerulonephropathy. 
ii. The diabetes patient with the renal pathological character of diabetic 
nephropathy. 
iii. The hypertension patient with the renal pathological character of 
hypertension related renal damage. 
iv. The patients with hyperuricemian and the renal pathological character of uric 
acid nephropathy 
Table 3.1. The diagnosis of metabolic syndrome associated renal disease: two levels of 
criterion 
3.1 Diagnosis of MS 
A diagnosis of metabolic syndrome associated kidney diseases must be based on the 
diagnosis of metabolic syndrome which is not only composed of central obesity, diabetes or 
prediabetes, hypertension, lipid metabolic disorder, etc., but also insulin resistance as its 
critical pathophysiological basis. the American Heart Association (AHA) along with the 
National Heart, Lung and Blood Institute issued an up-to-date version on the diagnosis of 
the metabolic syndrome.[105] The International Diabetes Federation (IDF) also provided a 
working definition for the syndrome (Table 3-2).[106]  
 
Clinical diagnosis criteria Categorical cut points 
Insulin resistance None 
Body weight 
Increased WC (population specific) 
plus any 2 of the following 
Lipid 
TG ≥150 mg/dL (1.7 mmol/L)or on TG Rx 
HDL-C <40 mg/dL (1.03 mmol/L)in men or <50 mg/dL (1.3 
mmol/L) in women or on HDL-C Rx 
Blood pressure 
≥130 mm Hg systolic or ≥85 mm Hg diastolic or on 
hypertension Rx 
Glucose ≥100 mg/dL(5.6 mmol/L), includes diabetes 
Table 3.2. Criteria for Clinical Diagnosis of Metabolic Syndrome (IDF, 2005) 
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The present AHA/NHLBI statement, in contrast to IDF, maintains the ATP III criteria except 
for minor modifications (Table 3-3).  
 
Measure (any 3 of 5 constitute 
diagnosis of metabolic syndrome) 
Categorical cut points 
Elevated waist circumference ≥102 cm (≥40 inches) in men, ≥88 cm (≥35 inches) in women 
Elevated triglycerides 
≥150 mg/dL (1.7 mmol/L) Or On drug treatment for 
elevated triglycerides 
Reduced HDL-C 
<40 mg/dL (1.03 mmol/L) in men<50 mg/dL (1.3 mmol/L) 
in women Or On drug treatment for reduced HDL-C 
Elevated blood pressure 
≥130 mm Hg systolic blood pressure, Or ≥85 mm Hg 
diastolic blood pressure Or On antihypertensive drug 
treatment in a patient with a history of hypertension 
Elevated fasting glucose 
≥100 mg/dL (5.6 mmol/L) or On drug treatment for 
elevated glucose 
Table 3.3. Criteria for Clinical Diagnosis of Metabolic Syndrome (AHA/NHLBI) 
It is suggested by the data of our recent community-based screening that the incidence of MS 
according to the diagnostic criteria of CDS was lower than that according to the diagnostic 
criteria of IDF. Some residents with MS mainly presentation of abdominal obesity would be 
missed diagnosis by the criteria base on BMI. In the components of MS, hypertension, 
abdominal obesity and lower high density lipoprotein were more common than others. 
3.2 Diagnosis of CKD 
The early evidences of metabolic syndrome associated kidney diseases might exist before 
the occurrence of clinical diabetes or hypertension, and it should include elevated or 
decreased GFR, microalbuminuria or even smaller proteins occurring in the urine before 
microalbuminuria, the presentation of renal pathological disorders existing before the 
clinical manifestation.  
According the K/DOQI definition and classification, CKD is defined as kidney damage or 
glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months or more, irrespective of 
cause. Kidney damage in many kidney diseases can be ascertained by the presence of 
albuminuria, defined as albumin-to-creatinine ratio >30 mg/g in two of three spot urine 
specimens. GFR can be estimated from calibrated serum creatinine and estimating 
equations.[107]  
There are many methods to determine GFR have been used, such as measuring GFR using 
exogenous markers, or endogenous markers, using exogenous marker is extremely 
inconvenience and is not used in clinical and epidemic practice. The often used endogenous 
markers are serum creatinine (SCr), usually calculated as creatinine clearance (CCr), and 
serum cystatin C. Most studies have shown that serum cystatin C levels correlate better with 
GFR than does serum creatinine alone, especially at higher levels of GFR. In practice, 
combining use of multiple indexes, such as SCr, age gender and race to evaluate GFR will be 
more accurate. So there many equations have been used to estimate GFR. The two most 
commonly used equations to estimate GFR are serum creatinine based: Cockcroft-Gault 
(CG) and the Modification of Diet in Renal Disease (MDRD) equations. A recent study 
involving a pooled analysis of individuals with chronic kidney disease proposed an 
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estimation equation that included serum cystatin C in addition to serum creatinine, age, sex, 
and race. Studies concluded this equation provided the most accurate estimates. 
The CG equation is as follows: 
CCr(ml/min) ={[140 – Age(yr)] × Weight(kg)}/SCr(mg/dl) ×72×(0.85, if female) 
The six variable MDRD equation is as follows: 
GFR= 170 ×(SCr)-0.999 × (Age)-0.176 × 0.762(if female) × 1.18(if black) ×(BUN)-0.170× (Alb)0.318 
where BUN is blood urea nitrogen and Alb is albumin. 
The abbreviated version or four variable version of the MDRD equation (ml/min per 1.73 
m2) is as follows: 
GFR = 186 × (SCr) 1.154 × (Age) 0.203 × 0.742(if female) × 1.212(if black) 
The equation base on SCr and serum CysC is as follow: 
eGFR = 177.6 ×( SCr)-0.65 × (CysC)-0.57  ×(Age)-0.20 × 0.82(if female) × 1.11 (if black) 
3.3 Renal pathological changes in metabolic syndrome 
There is a small sample retrospective design.[108] The histopathologic presentation of patients 
with metabolic syndrome compared with controls had a greater prevalence of tubular 
atrophy, interstitial fibrosis, and arterial sclerosis, suggesting microvascular disease. Patients 
with metabolic syndrome had greater global and segmental glomerulosclerosis. Glomerular 
volume and cross-sectional surface area were not different. The combined end point of 
tubular atrophy greater than 5%, interstitial fibrosis greater than 5%, and presence of arterial 
sclerosis was more prevalent in patients with metabolic syndrome than controls.  
4. Prevention and treatment 
Aggressive multitargeted management of the metabolic syndrome can also improve cardio 
vascular and renal outcomes and is highly recommended by the American Heart 
Association. Although no study has evaluated whether multiple interventions can reduce 
the incidence or progression of CKD in patients with the metabolic syndrome.[109]  
4.1 Lifestyle changes 
Lifestyle interventions are the first line therapies recommended for treatment of the 
metabolic syndrome. The essential and important measurements include weight reduction, 
regular exercise, and a low-calorie, low-fat diet. Yet few data are available to indicate that 
such lifestyle interventions can prevent or reverse renal damage.[109]  
4.2 Medication treatment 
If lifestyle change is not sufficient, then drug therapies for abnormalities in the individual 
risk factors may be indicated. Such as medicine for treatment of diabetes, hypertension, lipid 
disorder and hyperuricemia. 
4.2.1 Treatment of elevated blood glucose 
In metabolic syndrome patients with IFG (or IGT if assessed), weight reduction, increased 
physical activity, or both will delay (or prevent) the onset of type 2 diabetes mellitus. 
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Intensive glucose control to lower the glycated hemoglobin value to 6.5% yielded a 10% 
relative reduction in the combined outcome of major macrovascular and microvascular 
events, primarily as a consequence of a 21% relative reduction in nephropathy. 
Oral Antihyperglycemic Agents:[110] Metformin, thiazolidinediones and acarbose will lower 
risk for type 2 diabetes mellitus in people with IFG or IGT. The nonsulfonylurea insulin 
secretagogues repaglinide and nateglinide can be used in renal failure without dose 
adjustments. Metformin is contraindicated in renal failure because of the associated risk for 
lactic acidosis. It can be used at low dosages up to a creatinine clearance of 30 to 60 ml/min 
and should be avoided with clearances<30 ml/min. Although the metabolism of 
thiazolidinediones is unaffected by renal failure, they must be used with caution in this context 
because of their volume retaining effect with a risk for heart failure. The sulfonylureas 
(glyburide, gliclazide, glipizide, glibenclamide, tolbutamide, and chlorpropamide) have 
increased potency to prolong sulfonylurea induced hypoglycemia as the renal function 
decreases and are contraindicated in severe renal failure. ǂ-Glucosidase inhibitors (acarbose 
and miglitol) are also contraindicated in renal failure. 
Insulin therapy: Insulin therapy maybe benefits in glycaemic control, but not improves 
insulin resistance and metabolic syndrome. Insulin analogues, whose main objective is to 
stimulate physiologic insulin secretion, has opened new therapeutic possibilities in diabetic 
CRF patients.[111] Although only a few studies have evaluated the clinical efficacy and safety 
profile of insulin analogues in CRF patients, preliminary results appear hopeful. There is 
another concern of insulin injection for long term might be unfavourable, as ectogenous 
insulin may inhibit endogenous insulin secretion and results in the lack of the co-secretion 
of other beneficial substances such as C-peptide which is just now known to be potential in 
the treatment of diabetic nephropathy.[112]  
4.2.2 Treatment of elevated blood pressure 
In the presence of diabetes or chronic kidney disease, the blood pressure goal is <130/80 
mm Hg.  Mild elevations of blood pressure often can be effectively controlled with lifestyle 
therapies. Some investigators support angiotensin-converting enzyme (ACE) inhibitors as 
first-line therapy for hypertension in the metabolic syndrome, especially when either type 2 
diabetes mellitus or chronic renal disease is present. ARBs may be used in those who cannot 
tolerate ACE inhibitors or as an alternative to ACE inhibitors. 
4.2.3 Treatment of dyslipidemia 
According to ATP III, as long as LDL-C remains above goal level, LDL-C is the primary 
target of therapy even in the metabolic syndrome. Other lipid risk factors are secondary. The 
LDL-C goals depend on estimates of absolute risk. 
The main effects of Statin therapy are reduction of LDL-cholesterol, triglyceride and 
systemic inflammation, possible improvement of endothelial function and inhibition of renal 
endothelin 1-mediated proteinuria. The goal level of LDL-cholesterol: <1.80 mmol/l in very 
high-risk patients and <2.60 mmol/l in high-risk patients.[109]  
Fibrates and nicotinic acid are the most commonly used drugs for elevated TG and reduced 
HDL-C. The main effects of fibrates therapy are decrease of triglycerides, increase of HDL, 
increase of insulin sensitivity, anti-inflammatory and antihypertensive action, and also 
reduction of mesangium-induced glomerular matrix deposition.[109]  
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4.3 New treatment 
Islets transplantation or stem cell transplantation has shown very exciting future in more 
effectively controlling blood glucose and preventing and treating diabetes-associated organ 
damage. More early intervention and prevention targets have been found for metabolic 
syndrome associated kidney diseases. 
4.3.1 Islets transplantation 
Pancreas or Islets transplantation is indicated to treatment of type 1 diabetes which insulin 
is insufficient for normal glucose metabolism. After long term (more than five years) of 
normoglycemia, diabetic nephropathy will be reversed.[81] It is not clear that pancreas or 
Islets transplantation will be benefit to improve of type 2 diabetes. In fact, insulin resistance 
will be more serious after transplantation due to the use of immunosuppressive agent.[113] 
Our small sample of patients with type 2 diabetes and ESRD receive combined 
transplantation of islets and kidney shown reversion of the peripheral nerves and vascular 
diseases, and maybe a protection of renal graft from damage of hyperglycosemia. 
Islet transplantation is an effective therapy for insulin-dependent diabetes mellitus, based 
on the research data which indicated that islet transplantation could not only retrieve the 
glycometabolism disorders but also prevent and reverse diabetes-associated 
microangiopathy. According to the registration data of the International Organ 
Transplantation Center, there had been up to 1300 patients received islet transplantation by 
the end of 2006. More than 40 institutes have developed islet transplantation for totally 550 
cases of diabetic patients, since the Edmonton Islet Transplantation Protocol was available in 
2000. The growth rate increased markedly compared to the era before 2000. 
The islets isolated from donor’s pancreatic tissue, by means of enzyme digestion and 
centrifugal purification, are injected into recipients’ liver through portal vein. The 
transplanted islets locate in hepatic sinus, adjusting the synthesis of hepatic glycogen and 
reversing the disorders of glycometabolism through secreting insulin. Autogeneic islet 
transplantation is limited in patients received entire or partial resection of pancreas due to 
chronic pancreatitis and tumor. Allogeneic islet transplantation needs immunosuppressants 
and therefore is mainly suit for kidney transplant recipients with type I diabetes-associated 
renal failure. Along with the development of new immunosuppressants, the indications of 
islet transplantation are increasing. In recent years islet transplantation along has been 
applied in patients with “friable” type I diabetes with refractory severe hypoglycemia while 
without renal failure, and considered for patients with type II diabetes and complete lost of 
islets’ function. 
A four year cooperative study was carried out in 9 islet transplantation centers of USA, 
Canada and Europe and 36 cases of type I diabetes received islet transplantation according 
to coincident Edmondon Protocol. It was shown by the data that 16 cases were insulin-
independent one year after transplantation (16/36, 44%) and, among them, 5 cases were still 
insulin-independent after 2 years follow-up (5/16, 31%). The study proved the efficacy of 
Edmondon Protocol in significantly increasing the success rate of islet transplantation. 
Besides, it is indicated by the success of Edmondon islet transplantation protocol that islet 
transplantation along is also fit to patients with type I diabetes while it is not always needed 
to be performed together with renal transplantation. In recent years some islet transplant 
recipients without renal failure were only administered short-term of immunosuppressive 
treatment (Daclizum administered on day 1 and day 3) and good efficacy achieved, which 
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The surgical operation of islet transplantation is simple, but the isolation and the 
purification of islets belong to high-tech range. The skill and experience of operators are 
extremely important. Different operators have markedly different isolation results even they 
use the same pancreas from the same donor and apply the same isolation procedure. How 
to get enough functional islets from donor’s pancreas is the key technique for islet 
transplantation. Islet transplantation is a program needs multi-department and multi-
subject cooperation. A cooperation network should include endocrinologists, surgeons, 
transplantation center, net-serving staff, official administrators, transplant immunologists, 
transportation department. In addition, the qualities of a lot of procedures during 
transplantation can influence the result of islet transplantation, including patient selection, 
tissue matching, reservation and transportation, islet isolation and purification, islet 
implantation, blood glucose controlling during islet transplantation, immunosuppressant 
administration, and function evaluation after transplantation. The determination of islet cell 
auto-antibodies in recipients’ blood after transplantation is important for the prognosis of 
long-term islet transplantation efficacy. We should further investigate the relationship 
between the production of islet cell auto-antibodies and the survival of transplanted islets, 
and make sure if the auto-antibodies is the main factor resulting in the damage of 
transplanted islets. Islet cell auto-antigens can be produced with gene recombination and 
immune absorption column can be prepare with the auto-antigens and used to in time 
eliminate the auto-antibodies in patients’ blood, reducing islet damage induced by the 
antibodies and increase the long-term survival of transplanted islets. 
4.3.2 Stem cell transplantation 
Stem cell transplantation has shown effective in treatment of type 1 diabetes shown beta cell 
function increased,[114] and also in treatment of type 2 diabetes with significant increase of 
serum adiponectin and glucose tolerance.[115] Data from studies of NOD/SCID mice with 
diabetes shown that mesenchymal stem cells (MSCs) administration can prevent and treat 
diabetic nephropathy, prevent the pathological changes in the glomeruli and enhances their 
regeneration resulting in improved kidney function in diabetic animals.[116]  
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